GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » YoY EBITDA Growth

Race Oncology (ASX:RAC) YoY EBITDA Growth : 57.38% (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Race Oncology YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Race Oncology's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 57.38%.

Race Oncology's EBITDA per Share for the six months ended in Dec. 2024 was A$-0.03.

Race Oncology YoY EBITDA Growth Historical Data

The historical data trend for Race Oncology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Race Oncology YoY EBITDA Growth Chart

Race Oncology Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only 20.00 -38.89 -52.00 -9.21 -34.94

Race Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.70 -20.51 -69.44 -8.51 57.38

Race Oncology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Race Oncology's YoY EBITDA Growth for the fiscal year that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (A: Jun. 2024 )
=(EBITDA per Share (A: Jun. 2024 )-EBITDA per Share (A: Jun. 2023 ))/ | EBITDA per Share (A: Jun. 2023 ) |
=(-0.112--0.083)/ | -0.083 |
=-34.94 %

Race Oncology's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-0.026--0.061)/ | -0.061 |
=57.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Race Oncology YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Race Oncology's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Race Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » YoY EBITDA Growth
Comparable Companies
ASX:IMU ASX:ALA ASX:PAR ASX:DXB ASX:ACW ASX:AGN ASX:RCE ASX:EZZ ASX:ATH ASX:LTP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Website
https://www.raceoncology.com
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.